Biofrontera Inc.
Ameluz
superficial basal cell carcinoma (sBCC)
Countdown
84days
FDA decision · Sep 28, 2026
What's at stake
The FDA's approval decision on Ameluz for superficial basal cell carcinoma (sBCC) is due Sep 28, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“a PDUFA date for sBCC in September 2026,”